Ronald Virag

CETI ~Paris

www.medisexe.com

Papavérine

Epigastric artery

2a

2b

2c

Clamp

The first intracavernous injection in february 1981

It happened during a Michal 1

procedure

Early pionneers 1976-1980

In the meantime in Paris…

Group 1: « Non organic »

Group 2: « Arterial »

Group 3: « Venous and Mixed

Giles S Brindley

1983/ Phenoxybenzamine

Adrian W Zorgniotti

1983/ Papaverine-Phentolamine

11

« CERITINE »

Papaverine

Alphablockers

Dipyramidole

Atropine

PGE1

J. of Urology 1991

Self IC injections of etilefrine

0

1000

2000

3000

4000

5000

6000

7000

Total

ICI

Over 7000 patients on Intracavernous Injections

Ronald Virag

CETI-Paris

H.Sussman, P.Bouilly, C.Daniel, K.Shoukry, F.Nollet,

C.Richard, J.Floresco, H.Saltiel, D.Frydman, C.Lévy

Et Catherine Arnion

Académie de Chirurgie~Séance du 5 mai 2010

Why do you prefer ICI ?

Sure/ No performance

anxiety

Longer erections

Stay after ejaculation

Very few side effects

The Present

Research

Treatment

Diagnosis

Pivotal role of IC pharma test

Oral

ICI

Surgery

Treatment of a symptom

Cure or Prevent a disease

• VEGF ENDOTHELIAL GENE THERAPY

• ADIPOSE TISSUE STEM CELL THERAPY

• ICI OF STEM CELLS FROM THE NEURAL CREST

• AUTOLOGOUS CELLULAR THERAPY

Compounds mixing

NO donnors + Calcium blockers +

K channel openers

Improvement of IC Routes

Guided molecules

Micropumps

CETI

A new promising treatment for ED and Lapeyronie’s disease

AUTOLOGOUS CELLULAR THERAPY

Traitement de la Maladie de Lapeyronie par PRP + HLA-

Early Results in 19 patients

Follow up

Mean follow up 11 months

12 > 6 months

Complication

One hematoma

15/19 patients improved (74%)

8 excellent (patient quotation)

7 fair

Unchanged or Worsened 2